Yahya Naji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yahya Naji has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Nawal Adali
N.I.C.E." Research Team, "R.E.G.N.E." Research Laboratory, Faculty of Medicine and Pharmacy, Ibn Zohr University, Agadir, Morocco; Neurology, University Teaching Hospital Mohammed VI, Agadir, Morocco
8 shared publications- Najib Kissani
Laboratory of Clinical and Experimental Neuroscience, Faculty of Medicine, Cadi Ayyad University
7 shared publications Sara Laadami
N.I.C.E." Research Team, "R.E.G.N.E." Research Laboratory, Faculty of Medicine and Pharmacy, Ibn Zohr University, Agadir, Morocco; Neurology, University Teaching Hospital Mohammed VI, Agadir, Morocco
6 shared publicationsNajib Kissani
Medical Research Center, Marrakech Medical School, University Cadi Ayyad, Marrakesh, Morocco; Department of Neurology, University Teaching Hospital Mohammed VI, Marrakesh, Morocco
4 shared publications- Raymond Klevor
Neuroscience Research Laboratory, Faculty of Medicine and Pharmacy of Marrakesh, Cadi Ayaad University, Marrakech 40000, Morocco
3 shared publications Athanase Millogo
Université Joseph KI-ZERBO, Ouagadougou, Burkina Faso
2 shared publications
Latest Publications
- 29 March 2026
- Published by Elsevier in Epilepsy Research
- Vol. 223, 107784
EEG coverage in Africa: How can the gap be covered?
- 29 March 2026
- Published by Elsevier in Epilepsy Research
- Vol. 223, 107784
EEG coverage in Africa: How can the gap be covered?
- Open Access
- 25 June 2025
- Published by MDPI AG in Psychiatry International
- Vol. 6 (3) , 75
A Complex, Multi-Faceted Condition Requires a Holistic Non-Pharmacological Therapy: Making the Case for Morita Therapy in Parkinson’s Disease
Psychotherapy has become a necessity for Parkinson’s patients suffering from anxiety disorder. There are different types of therapy; for example, Morita therapy, first proposed in 1919, is a psychological therapy. It is mainly used as an alternative therapy in Asian countries such as Japan and China. Morita therapy focuses on accepting emotions, including anxiety, rather than trying to reduce them. Although it has had an impact on treating anxiety disorder in other populations, there have been no studies to date investigating the evidence and effects of Morita therapy on anxiety disorder in Parkinson’s patients. This opinion article focuses on conducting a literature review to identify relevant studies on the applications of Morita therapy in anxiety disorders and explore the possibility of proposing it as a treatment option for Parkinson’s patients.
- 25 June 2025
- Published by MDPI AG in Psychiatry International
- Vol. 6 (3) , 75
Open AccessA Complex, Multi-Faceted Condition Requires a Holistic Non-Pharmacological Therapy: Making the Case for Morita Therapy in Parkinson’s Disease
Psychotherapy has become a necessity for Parkinson’s patients suffering from anxiety disorder. There are different types of therapy; for example, Morita therapy, first proposed in 1919, is a psychological therapy. It is mainly used as an alternative therapy in Asian countries such as Japan and China. Morita therapy focuses on accepting emotions, including anxiety, rather than trying to reduce them. Although it has had an impact on treating anxiety disorder in other populations, there have been no studies to date investigating the evidence and effects of Morita therapy on anxiety disorder in Parkinson’s patients. This opinion article focuses on conducting a literature review to identify relevant studies on the applications of Morita therapy in anxiety disorders and explore the possibility of proposing it as a treatment option for Parkinson’s patients.
- Open Access
- 13 June 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (6) , 458
HLA-DRB1 and DQB1 Allelic Polymorphism and Multiple Sclerosis in a Moroccan Population
Introduction: Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system (CNS) that leads to inflammation and demyelination, manifesting in either a relapsing–remitting or progressive form. As a multifactorial disease, MS involves both genetic and environmental factors, with a known significant contribution from human leukocyte antigen (HLA) genes, mainly represented by the HLA-DRB1 and HLA-DQB1 loci, which have been linked to either susceptibility or protection, but variably across populations and ethnic groups. We aimed to study the distribution and polymorphism of HLA-DRB1 and HLA-DQB1 alleles in a population with MS from the southern Moroccan region, in comparison with healthy controls. Materials and Methods: A cross-sectional study was conducted over a period of 2 years (2022–2024) in a MS cohort including 40 patients and 100 healthy controls. DRB1 and DQB1 HLA genotyping was performed using a high-resolution reverse sequence-specific oligonucleotide (SSO) method, based on the Luminex system (xMAP technology, One lambda®). Data were analyzed using SPSS 26; differences in allele frequencies were evaluated by the Chi-square test and Fisher’s exact test. OR (95% CI) was calculated, and FDR corrections were applied for multiple testing. Results: Among the various HLA-DRB1 and DQB1 alleles studied, including those considered as predisposing to MS, the DQB1*02:01 and DRB1*15:01 alleles were more prevalent in MS patients, with 40% and 8.8% vs. 16% and 4.08% in controls respectively, although these differences were not statistically significant (p = 0.06 and p = 0.12). Likewise, the DRB1*15:01-DQB1*06:02 association was significantly more prevalent in the MS group (9%, p = 0.004). In contrast, the DRB1*07:01 allele, linked to protection against MS in many populations, was significantly predominant in controls (17%, p = 0.004). Similarly, the DRB1*07:01–DQB*02:01 combination was rather more frequent in controls (12%, p = 0.01). Confronted to MS clinical forms, we remarkably noted that the DRB1*13:03 allele was found only among relapsing–remitting MS (RRMS) patients (6%, p = 0.003), while DQB1*02:01 was significantly associated with RRMS (42.1%) and primary progressive MS (41%, p = 0.001), with an intermediate Expanded Disability Status Scale (EDSS) score, which may indicate a possible link with disease progression and severity. Conclusions: The results of our study highlighted particular HLA alleles, DRB1 and DQB1, alone or in combination, as potential immunogenic factors of susceptibility to MS in a population from southern Morocco, while other alleles seem rather to protect against the disease. This HLA polymorphism is also reflected in the clinical forms of the disease, showing a tendency toward severity for certain alleles. However, such preliminary results need to be consolidated and confirmed by studies carried out on a larger population sample, and compared with others on a national scale.
- 13 June 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (6) , 458
Open AccessHLA-DRB1 and DQB1 Allelic Polymorphism and Multiple Sclerosis in a Moroccan Population
Introduction: Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system (CNS) that leads to inflammation and demyelination, manifesting in either a relapsing–remitting or progressive form. As a multifactorial disease, MS involves both genetic and environmental factors, with a known significant contribution from human leukocyte antigen (HLA) genes, mainly represented by the HLA-DRB1 and HLA-DQB1 loci, which have been linked to either susceptibility or protection, but variably across populations and ethnic groups. We aimed to study the distribution and polymorphism of HLA-DRB1 and HLA-DQB1 alleles in a population with MS from the southern Moroccan region, in comparison with healthy controls. Materials and Methods: A cross-sectional study was conducted over a period of 2 years (2022–2024) in a MS cohort including 40 patients and 100 healthy controls. DRB1 and DQB1 HLA genotyping was performed using a high-resolution reverse sequence-specific oligonucleotide (SSO) method, based on the Luminex system (xMAP technology, One lambda®). Data were analyzed using SPSS 26; differences in allele frequencies were evaluated by the Chi-square test and Fisher’s exact test. OR (95% CI) was calculated, and FDR corrections were applied for multiple testing. Results: Among the various HLA-DRB1 and DQB1 alleles studied, including those considered as predisposing to MS, the DQB1*02:01 and DRB1*15:01 alleles were more prevalent in MS patients, with 40% and 8.8% vs. 16% and 4.08% in controls respectively, although these differences were not statistically significant (p = 0.06 and p = 0.12). Likewise, the DRB1*15:01-DQB1*06:02 association was significantly more prevalent in the MS group (9%, p = 0.004). In contrast, the DRB1*07:01 allele, linked to protection against MS in many populations, was significantly predominant in controls (17%, p = 0.004). Similarly, the DRB1*07:01–DQB*02:01 combination was rather more frequent in controls (12%, p = 0.01). Confronted to MS clinical forms, we remarkably noted that the DRB1*13:03 allele was found only among relapsing–remitting MS (RRMS) patients (6%, p = 0.003), while DQB1*02:01 was significantly associated with RRMS (42.1%) and primary progressive MS (41%, p = 0.001), with an intermediate Expanded Disability Status Scale (EDSS) score, which may indicate a possible link with disease progression and severity. Conclusions: The results of our study highlighted particular HLA alleles, DRB1 and DQB1, alone or in combination, as potential immunogenic factors of susceptibility to MS in a population from southern Morocco, while other alleles seem rather to protect against the disease. This HLA polymorphism is also reflected in the clinical forms of the disease, showing a tendency toward severity for certain alleles. However, such preliminary results need to be consolidated and confirmed by studies carried out on a larger population sample, and compared with others on a national scale.
- Open Access
- 26 May 2025
- Published by Springer Nature in Cureus
- Vol. 17 (5) , e84823
Bulbar-Onset Amyotrophic Lateral Sclerosis Unmasked by General Anesthesia: A Case Report
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that primarily affects the motor neurons in the brain and spinal cord, resulting in severe muscular weakness, atrophy, and loss of motor control. Patients with ALS are often highly sensitive to anesthetic drugs, specifically neuromuscular blocking agents, which can exacerbate muscle weakness and contribute to prolonged postoperative recovery times. In this article, we report a case of bulbar ALS diagnosed after postoperative extubation failure in a 51-year-old patient. Practitioners should consider this disease in cases of difficult postoperative ventilatory weaning and should be aware of the impact of surgery and anaesthesia on disease progression.
- 26 May 2025
- Published by Springer Nature in Cureus
- Vol. 17 (5) , e84823
Open AccessBulbar-Onset Amyotrophic Lateral Sclerosis Unmasked by General Anesthesia: A Case Report
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that primarily affects the motor neurons in the brain and spinal cord, resulting in severe muscular weakness, atrophy, and loss of motor control. Patients with ALS are often highly sensitive to anesthetic drugs, specifically neuromuscular blocking agents, which can exacerbate muscle weakness and contribute to prolonged postoperative recovery times. In this article, we report a case of bulbar ALS diagnosed after postoperative extubation failure in a 51-year-old patient. Practitioners should consider this disease in cases of difficult postoperative ventilatory weaning and should be aware of the impact of surgery and anaesthesia on disease progression.
- Open Access
- 17 February 2025
- Published by Springer Nature in Cureus
- Vol. 17 (2) , e79157
Impact of Ramadan Fasting on Patients with Epilepsy: A Systematic Review
Ramadan fasting, a religious practice observed by Muslims worldwide, involves abstaining from food, drink, and other specified activities from dawn to sunset. For patients with epilepsy (PWE), fasting during Ramadan presents unique challenges due to potential disruptions in medication schedules, changes in sleep patterns, and alterations in diet, which can influence seizure control. This literature review synthesizes current research on the impact of Ramadan fasting on seizure frequency, quality of life (QoL), and physiological changes in PWE. The review also examines existing clinical guidelines for managing epilepsy during Ramadan and identifies significant gaps in the literature that warrant further investigation. Through a systematic search of three electronic databases, namely PubMed, ScienceDirect, and Google Scholar, relevant studies were identified and analyzed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The review reveals a complex relationship between fasting and epilepsy, with some patients experiencing stable or improved seizure control, while others face increased seizure risk. Medication adherence, sleep disruption, and individual patient characteristics are critical in determining outcomes. The findings underscore the importance of personalized care strategies for PWE who wish to fast during Ramadan, including pre-Ramadan consultations, tailored medication regimens, and ongoing monitoring throughout the fasting period. Despite the progress made in understanding the effects of Ramadan fasting on epilepsy, significant gaps remain. The review highlights the need for future studies to assess the long-term impact of fasting, research on diverse patient populations, and the development of evidence-based clinical guidelines. Addressing these gaps is essential to improve the management of epilepsy during Ramadan and ensure that patients can safely observe their religious practices while maintaining optimal seizure control.
- 17 February 2025
- Published by Springer Nature in Cureus
- Vol. 17 (2) , e79157
Open AccessImpact of Ramadan Fasting on Patients with Epilepsy: A Systematic Review
Ramadan fasting, a religious practice observed by Muslims worldwide, involves abstaining from food, drink, and other specified activities from dawn to sunset. For patients with epilepsy (PWE), fasting during Ramadan presents unique challenges due to potential disruptions in medication schedules, changes in sleep patterns, and alterations in diet, which can influence seizure control. This literature review synthesizes current research on the impact of Ramadan fasting on seizure frequency, quality of life (QoL), and physiological changes in PWE. The review also examines existing clinical guidelines for managing epilepsy during Ramadan and identifies significant gaps in the literature that warrant further investigation. Through a systematic search of three electronic databases, namely PubMed, ScienceDirect, and Google Scholar, relevant studies were identified and analyzed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The review reveals a complex relationship between fasting and epilepsy, with some patients experiencing stable or improved seizure control, while others face increased seizure risk. Medication adherence, sleep disruption, and individual patient characteristics are critical in determining outcomes. The findings underscore the importance of personalized care strategies for PWE who wish to fast during Ramadan, including pre-Ramadan consultations, tailored medication regimens, and ongoing monitoring throughout the fasting period. Despite the progress made in understanding the effects of Ramadan fasting on epilepsy, significant gaps remain. The review highlights the need for future studies to assess the long-term impact of fasting, research on diverse patient populations, and the development of evidence-based clinical guidelines. Addressing these gaps is essential to improve the management of epilepsy during Ramadan and ensure that patients can safely observe their religious practices while maintaining optimal seizure control.
- Open Access
- 29 September 2024
- Published by Springer Nature in Cureus
- Vol. 16 (9) , e70420
Essential Palatal Tremor Following COVID-19 Vaccine: A Case Report
Palatal tremor (PT) is an infrequent disorder characterized by abnormal movement distinguished into symptomatic palatal tremor (SPT) and essential palatal tremor (EPT). SPT can have various causes, including damage to the Guillain-Mollaret triangle and hypertrophy of the inferior olive. In contrast, EPT is often associated with clicking sounds in the ears with normal imaging results and may have a functional origin. We describe a case of a 20-year-old girl presenting with clinical symptoms of PT two days after receiving the SARS-CoV-2 AstraZeneca vaccine. The patient had persistent audible clicks associated with rhythmic contractions of the soft palate. Complete resolution of symptoms occurred two days after the administration of oral clonazepam. This is the first known case of PT caused by the SARS-CoV-2 AstraZeneca vaccine.
- 29 September 2024
- Published by Springer Nature in Cureus
- Vol. 16 (9) , e70420
Open AccessEssential Palatal Tremor Following COVID-19 Vaccine: A Case Report
Palatal tremor (PT) is an infrequent disorder characterized by abnormal movement distinguished into symptomatic palatal tremor (SPT) and essential palatal tremor (EPT). SPT can have various causes, including damage to the Guillain-Mollaret triangle and hypertrophy of the inferior olive. In contrast, EPT is often associated with clicking sounds in the ears with normal imaging results and may have a functional origin. We describe a case of a 20-year-old girl presenting with clinical symptoms of PT two days after receiving the SARS-CoV-2 AstraZeneca vaccine. The patient had persistent audible clicks associated with rhythmic contractions of the soft palate. Complete resolution of symptoms occurred two days after the administration of oral clonazepam. This is the first known case of PT caused by the SARS-CoV-2 AstraZeneca vaccine.
- Open Access
- 23 August 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1435075
Anti-seizure medication prescription preferences: a Moroccan multicenter study
Background: The management of epilepsy is mainly based on antiseizure medications (ASMs). More than 20 ASMs have been introduced in clinical practice, providing a multitude of prescription choices. To date, there are no published data on the trends in ASMs prescriptions in Morocco. Therefore, we conducted a survey among practicing neurologists in seven tertiary referral hospitals in Morocco to study the current ASMs prescription preferences and their modifying factors.Methods: Our descriptive and analytical cross-sectional study was based on a survey sent between January and April 2022 to neurologists practicing in seven tertiary referral hospitals in Morocco. Information regarding the prescription of ASMs was collected using an exploitation form and analyzed using the SPSS version 13 software.Results: Based on questionnaire responses, our results showed that Valproic acid (96.3%) and Lamotrigine (59.8%) were the two most prescribed ASMs for generalized seizure types. For focal seizure types, Carbamazepine (98.8%) and Levetiracetam (34.1%) were the most commonly prescribed drugs, whereas for combined focal and generalized seizure types, the combination of Valproic acid and Carbamazepine (38.55%) was the most prescribed. Phenobarbital was the most commonly prescribed ASM for status epilepticus (40.2%). These prescription preferences were mainly due to seizure types, cost, health insurance coverage, years of experience, and additional epileptology training (p < 0.05).Conclusion: Our results show a shift in the prescription of ASMs in Morocco. Similar to many other countries, valproic acid and carbamazepine are considered the first-line treatments for generalized and focal seizure types. Some factors remain as major challenges in enhancing epilepsy management in Morocco.
- 23 August 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1435075
Open AccessAnti-seizure medication prescription preferences: a Moroccan multicenter study
Background: The management of epilepsy is mainly based on antiseizure medications (ASMs). More than 20 ASMs have been introduced in clinical practice, providing a multitude of prescription choices. To date, there are no published data on the trends in ASMs prescriptions in Morocco. Therefore, we conducted a survey among practicing neurologists in seven tertiary referral hospitals in Morocco to study the current ASMs prescription preferences and their modifying factors.Methods: Our descriptive and analytical cross-sectional study was based on a survey sent between January and April 2022 to neurologists practicing in seven tertiary referral hospitals in Morocco. Information regarding the prescription of ASMs was collected using an exploitation form and analyzed using the SPSS version 13 software.Results: Based on questionnaire responses, our results showed that Valproic acid (96.3%) and Lamotrigine (59.8%) were the two most prescribed ASMs for generalized seizure types. For focal seizure types, Carbamazepine (98.8%) and Levetiracetam (34.1%) were the most commonly prescribed drugs, whereas for combined focal and generalized seizure types, the combination of Valproic acid and Carbamazepine (38.55%) was the most prescribed. Phenobarbital was the most commonly prescribed ASM for status epilepticus (40.2%). These prescription preferences were mainly due to seizure types, cost, health insurance coverage, years of experience, and additional epileptology training (p < 0.05).Conclusion: Our results show a shift in the prescription of ASMs in Morocco. Similar to many other countries, valproic acid and carbamazepine are considered the first-line treatments for generalized and focal seizure types. Some factors remain as major challenges in enhancing epilepsy management in Morocco.
- Open Access
- 30 June 2024
- Published by Springer Nature in Cureus
- Vol. 16 (6)
Double Cortex Syndrome: An Unusual Cause of Seizures
Gray matter heterotopia (GMH) is caused by abnormal neuronal migration during brain development. Subcortical band heterotopia (SBH), or double cortex, is a rare variant of GMH that mainly affects female patients with epilepsy (PWE) with different degrees of mental retardation. We present the case of a 25-yearold woman who was admitted to the neurology department of our tertiary hospital with generalized tonicclonic seizures. Her mother had a normal antenatal period and a history of labor. There was a history of immediate crying and normal appearance, pulse, grimace, activity, and respiration (APGAR) scores. She had delayed milestones, which affected various categories of child development. Physical examination revealed a global developmental delay. Laboratory values, including complete blood count, serum calcium, and arterial blood gas tests, were all within normal limits. An EEG showed significant abnormalities suggestive of epilepsy. An MRI of the brain showed a continuous band of gray matter located deep and parallel to the cortex in both cerebral hemispheres, suggesting double cortex syndrome (DCS).
- 30 June 2024
- Published by Springer Nature in Cureus
- Vol. 16 (6)
Open AccessDouble Cortex Syndrome: An Unusual Cause of Seizures
Gray matter heterotopia (GMH) is caused by abnormal neuronal migration during brain development. Subcortical band heterotopia (SBH), or double cortex, is a rare variant of GMH that mainly affects female patients with epilepsy (PWE) with different degrees of mental retardation. We present the case of a 25-yearold woman who was admitted to the neurology department of our tertiary hospital with generalized tonicclonic seizures. Her mother had a normal antenatal period and a history of labor. There was a history of immediate crying and normal appearance, pulse, grimace, activity, and respiration (APGAR) scores. She had delayed milestones, which affected various categories of child development. Physical examination revealed a global developmental delay. Laboratory values, including complete blood count, serum calcium, and arterial blood gas tests, were all within normal limits. An EEG showed significant abnormalities suggestive of epilepsy. An MRI of the brain showed a continuous band of gray matter located deep and parallel to the cortex in both cerebral hemispheres, suggesting double cortex syndrome (DCS).
- Open Access
- 30 March 2024
- Published by Springer Nature in Cureus
- Vol. 16 (3) , e57289
Cochleovestibular Signs As the First Manifestation of Fabry Disease: A Case Report and Literature Review
Fabry disease (FD) is an X-linked lysosomal storage disorder characterized by alpha-galactosidase A deficiency, resulting in globotriaosylceramide accumulation and diverse clinical manifestations. We report a case of a 22-year-old male presenting with cochleovestibular disorders as the initial FD manifestation, alongside a literature review. Diagnostic evaluation revealed reduced alpha-galactosidase A activity, confirming FD. Cochleovestibular involvement, although underexplored, significantly affects FD patients, often presenting with sudden deafness or sensorineural hearing loss. Prompt diagnosis and enzyme replacement therapy are crucial for managing FD. Otolaryngologists play a key role in early detection and intervention. This case underscores the importance of considering FD in cases of hearing loss, tinnitus, or vertigo, emphasizing the need for heightened awareness among healthcare providers.
- 30 March 2024
- Published by Springer Nature in Cureus
- Vol. 16 (3) , e57289
Open AccessCochleovestibular Signs As the First Manifestation of Fabry Disease: A Case Report and Literature Review
Fabry disease (FD) is an X-linked lysosomal storage disorder characterized by alpha-galactosidase A deficiency, resulting in globotriaosylceramide accumulation and diverse clinical manifestations. We report a case of a 22-year-old male presenting with cochleovestibular disorders as the initial FD manifestation, alongside a literature review. Diagnostic evaluation revealed reduced alpha-galactosidase A activity, confirming FD. Cochleovestibular involvement, although underexplored, significantly affects FD patients, often presenting with sudden deafness or sensorineural hearing loss. Prompt diagnosis and enzyme replacement therapy are crucial for managing FD. Otolaryngologists play a key role in early detection and intervention. This case underscores the importance of considering FD in cases of hearing loss, tinnitus, or vertigo, emphasizing the need for heightened awareness among healthcare providers.
- Open Access
- 14 March 2024
- Published by Springer Nature in Cureus
- Vol. 16 (3)
Steroid-Responsive Encephalopathy Associated With Autoimmune Thyroiditis Presenting With Parkinsonism
Steroid -responsive encephalopathy associated with autoimmune thyroiditis (SREAT) is a rare condition defined as encephalopathy with a positive antithyroid antibody. We report the case of a 52 -year -old woman who presented with Parkinsonism associated with Hashimoto's thyroiditis. A few similar cases have been reported. Our patient responded well to corticosteroids with a significant reduction in symptoms. Diagnosis can pose a significant challenge in SREAT cases because of its variable clinical presentation. Therefore, we recommend evaluating thyroid function and thyroid autoantibodies in the context of acute and subacute encephalopathy. In the elderly population, SREAT, as a cause of Parkinsonism, should not be forgotten because of its simple treatment and significant improvements in neurological symptoms.
- 14 March 2024
- Published by Springer Nature in Cureus
- Vol. 16 (3)
Open AccessSteroid-Responsive Encephalopathy Associated With Autoimmune Thyroiditis Presenting With Parkinsonism
Steroid -responsive encephalopathy associated with autoimmune thyroiditis (SREAT) is a rare condition defined as encephalopathy with a positive antithyroid antibody. We report the case of a 52 -year -old woman who presented with Parkinsonism associated with Hashimoto's thyroiditis. A few similar cases have been reported. Our patient responded well to corticosteroids with a significant reduction in symptoms. Diagnosis can pose a significant challenge in SREAT cases because of its variable clinical presentation. Therefore, we recommend evaluating thyroid function and thyroid autoantibodies in the context of acute and subacute encephalopathy. In the elderly population, SREAT, as a cause of Parkinsonism, should not be forgotten because of its simple treatment and significant improvements in neurological symptoms.